SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-017881
Filing Date
2021-03-26
Accepted
2021-03-26 08:37:54
Documents
4
Period of Report
2021-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea138463-8k_tffpharma.htm 8-K 30471
2 UNDERWRITING AGREEMENT DATED AS OF MARCH 26, 2021 AMONG THE COMPANY, LUNG THERAP ea138463ex1-1_tffpharma.htm EX-1.1 206993
3 OPINION OF GREENBERG TRAURIG, LLP ea138463ex5-1_tffpharma.htm EX-5.1 7638
4 PRESS RELEASE DATED MARCH 26, 2021 REGARDING PRICING OF THE OFFERING OF COMMON S ea138463ex99-1_tffpharma.htm EX-99.1 6769
  Complete submission text file 0001213900-21-017881.txt   253002
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 21774833
SIC: 2834 Pharmaceutical Preparations